PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57237-019-99) bottles, Distributed by: Rising Pharmaceuticals, Inc., East Brunswick, NJ

Reported: December 11, 2024 Initiated: November 19, 2024 #D-0107-2025

Product Description

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57237-019-99) bottles, Distributed by: Rising Pharmaceuticals, Inc., East Brunswick, NJ

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Details

Units Affected
233,003 bottles
Distribution
Nationwide.
Location
East Brunswick, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57237-019-99) bottles, Distributed by: Rising Pharmaceuticals, Inc., East Brunswick, NJ. Recalled by Rising Pharma Holding, Inc.. Units affected: 233,003 bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on December 11, 2024. Severity: Moderate. Recall number: D-0107-2025.